Empagliflozin

Also Known As: Empagliflozin, Jardiance

Empagliflozin (trade name Jardiance) is a drug of the gliflozin class, approved for the treatment of type 2 diabetes in adults in 2014. It was developed by Boehringer Ingelheim and Eli Lilly and Company.^[1]

Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and causes sugar in the blood to be excreted by the kidneys and eliminated in urine.

All Treatments

Average Effectiveness

This is the Average effectiveness per ailment as reported by our participants (you).

Effectiveness:

0 = No improvement or Worse
1 = Slight improvement
2 = Moderate Improvement
3 = Significant Improvement
4 = Cured

Order By

Type of Treatment

Date Range

Minimum Number of Users

Embed

Complete a survey on Empagliflozin to help the CureCrowd community

If you have tried to treat this ailment, please complete the following form to help us better our data, and help guide people to the best possible treatments. CureCrowd is a public resource with absolutely no vested interest in the outcomes of our studies.